Eli Lilly and Company announced a definitive agreement to acquire Aderum Biotechnologies and its leading candidate Ixo-vec. 1 ...

AI transforms pharmaceutical operations by automating workflows, ensuring transparency, and enhancing compliance, driving ...

PE: Could DTC programs help simplify the drug-pricing system? O’Dell: I’m guessing that the pharmaceutical manufacturers are ...

The DTC model aligns with Most-Favored-Nation pricing, aiming to close the US drug price gap with other high-income countries ...

In today’s Pharmaceutical Executive Daily, we cover market reaction to Novo Nordisk’s recent board shake-up, MJH Life Sciences’ acquisition of BPD Healthcare to strengthen its health system reach, and ...

Elevara Medicines secured $70 million in Series A funding to advance ELV001's Phase II trial for rheumatoid arthritis and explore other chronic inflammatory conditions. Pharma investments surge as ...

Moderna announced its decision to cease development of its vaccine mRNA-1647, which was being designed to treat birth defects ...

Alkermes acquires Avadel for $2.1 billion, enhancing its sleep medicine market presence and commercial portfolio with Lumryz. The acquisition supports Alkermes' development pipeline for central ...

Pharmaceutical Executive: What impact will DTC programs have on prescription drug prices? Chris O’Dell: I’m optimistic that they will have an impact in the long term. In the near term, however, what ...

MJH Life Sciences’ acquisition of BPD Healthcare represents a major expansion of strategic capabilities for MJH across ...

In today’s Pharmaceutical Executive Daily, we cover major leadership changes at Novo Nordisk, Kenvue’s request for the FDA to ...

Novo Nordisk's board changes stem from disagreements with the Novo Nordisk Foundation over board composition and strategic ...